These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 20436104

  • 1. How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
    Migliorati CA, Mattos K, Palazzolo MJ.
    J Am Dent Assoc; 2010 May; 141(5):562-6. PubMed ID: 20436104
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
    Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS, Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators.
    J Oral Maxillofac Surg; 2010 Feb; 68(2):243-53. PubMed ID: 19772941
    [Abstract] [Full Text] [Related]

  • 3. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R.
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract] [Full Text] [Related]

  • 4. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD.
    Drug Saf; 2006 Oct; 29(12):1133-52. PubMed ID: 17147460
    [Abstract] [Full Text] [Related]

  • 5. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W, Emkey R, Civitelli R.
    Drug Saf; 2007 Oct; 30(9):755-63. PubMed ID: 17722968
    [Abstract] [Full Text] [Related]

  • 6. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM, Arora S, Farag AF, Guber HA.
    Endocr Pract; 2007 Aug; 13(3):232-8. PubMed ID: 17599853
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT, Amenedo C, Freeman K, Kraut RA.
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [Abstract] [Full Text] [Related]

  • 9. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia.
    Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, Kim KJ, Rhee Y, Lim SK.
    Osteoporos Int; 2010 May; 21(5):847-53. PubMed ID: 19633881
    [Abstract] [Full Text] [Related]

  • 10. Awareness and education of patients receiving bisphosphonates.
    Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S.
    J Craniomaxillofac Surg; 2012 Apr; 40(3):277-82. PubMed ID: 21612939
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
    Nomura T, Shibahara T, Uchiyama T, Yamamoto N, Shibui T, Yakushiji T, Watanabe A, Muramatsu K, Ogane S, Murayama M, Sekine R, Nakata E, Fujimoto Y.
    Bull Tokyo Dent Coll; 2013 Apr; 54(2):117-25. PubMed ID: 23903583
    [Abstract] [Full Text] [Related]

  • 12. Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis.
    Zahrowski JJ.
    Am J Orthod Dentofacial Orthop; 2009 Mar; 135(3):361-74. PubMed ID: 19268836
    [Abstract] [Full Text] [Related]

  • 13. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.
    Koka S, Clarke BL, Amin S, Gertz M, Ruggiero SL.
    Int J Prosthodont; 2007 Mar; 20(2):115-22. PubMed ID: 17455429
    [Abstract] [Full Text] [Related]

  • 14. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
    Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay JW.
    Gen Dent; 2010 Mar; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
    [Abstract] [Full Text] [Related]

  • 15. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [Abstract] [Full Text] [Related]

  • 16. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R, Need A, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract] [Full Text] [Related]

  • 18. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A, Payne AG, Zafar S.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [Abstract] [Full Text] [Related]

  • 19. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
    Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S.
    Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
    [Abstract] [Full Text] [Related]

  • 20. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
    Jeffcoat M, Watts NB.
    Gen Dent; 2008 Oct; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.